It is fair to say that where we have tended to lose cases or where we see cases brought is under this idea of the fair and equitable treatment of the investor. It's not really under the expropriation heading. It's not that we're losing because panels have come in and said, “Canada, what you did is really bad by implementing this new substantive, legal obligation.” Where Canada loses is when people say, “Wait a second, you told the investor one thing one day and the next day, somebody else gave you some more money and you changed your mind,” or they say, “We had a deal with you. We gave you some money. You told us there were these regulations. We incurred costs and then you just changed your mind because some municipal government said it didn't have to pay because the federal government's going to pay for it in effect.” Those are the cases we actually lose.
I don't think it changes our ability to enact environmental law or pharmaceutical policy that we choose. What it says is that we have to be more careful when we legislate so that we don't discriminate against particular investors when we do it, and that we do it in a way that conforms to some sort of notion of due process, for lack of a better word. I don't think it really does hurt our ability to substantially legislate in those fields.